Reversal of resistance to oxazaphosphorines

Current Cancer Drug Targets

Volumn 6, Issue 5, 2006, Pages 385-407

  Zhang, Jing ^a   Tian, Quan ^a   Zhu, Yi Zhun ^b   Xu, An Long ^a   Zhou, Shu Feng ^a,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cyclophosphamide; Ifosfamide; Oxazaphosphorine; Pharmacogenetics; Resistance; Reversing agents

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; OXAZAPHOSPHORINE; RETROVIRUS VECTOR; THIOL; TROFOSFAMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CELL DEATH; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG ABSORPTION; DRUG METABOLISM; DRUG RESISTANCE; GENE DELIVERY SYSTEM; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PHARMACOGENETICS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHARMACOGENETICS;

EID: 33745915849     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906777723967     Document Type: Review

References (321)

1. Zhang, J.; Tian, Q.; Zhou, S. F. Clinical pharmacology of cyclophosphamide and ifosfamide. Curr. Drug Ther. 2006, 1, 104-168.
2. Gilman, A. The initial clinical trial of nitrogen mustard. Am. J. Surg. 1963, 105, 574-578.
3. Fleming, R. A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997, 17, 146S-154S.
4. Brock, N.; Hilgard, P.; Peukert, M.; Pohl, J.; Sindermann, H. Basis and new developments in the field of oxazaphosphorines. Cancer Invest. 1988, 6, 513-532.
5. Chen, C. S.; Lin, J. T.; Goss, K. A.; He, Y. A.; Halpert, J. R.; Waxman, D. J. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol. Pharmacol. 2004, 65, 1278-1285.
6. Rooseboom, M.; Commandeur, J. N.; Vermeulen, N. P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 2004, 56, 53-102.
7. Barile-Fabris, L.; Ariza-Andraca, R.; Olguin-Ortega, L.; Jara, L. J.; Fraga-Mouret, A.; Miranda-Limon, J. M.; Fuentes de la Mata, J.; Clark, P.; Vargas, F.; Alocer-Varela, J. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann. Rheum. Dis. 2005, 64, 620-625.
8. Ginzler, E. M.; Moldovan, I. Systemic lupus erythematosus trials: successes and issues. Curr. Opin. Rheumatol. 2004, 16, 499-504.
9. Beimler, J. H.; Andrassy, K. Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? Pediatr. Nephrol. 2004, 19, 949-955.
10. Petri, M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 2004, 13, 366-371.
11. Gehi, A.; Webb, A.; Nolte, M.; Davis, J., Jr. Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum. 2003, 48, 1067-1070.
12. Leandro, M. J.; Edwards, J. C.; Cambridge, G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 2002, 61, 883-888.
13. Keystone, E. C. B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatol. (Oxford) 2005, 44(Suppl 2), II8-12.
14. Verburg, R. J.; Sont, J. K.; van Laar, J. M. Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation. Arthritis Rheum. 2005, 52, 421-424.
15. Edwards, J. C.; Leandro, M. J.; Cambridge, G. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr. Dir. Autoimmun. 2005, 8, 175-92.
16. Zhang, J.; Tian, Q.; Chan, S. Y.; Duan, W.; Zhou, S. Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist. Updat. 2005, 8, 271-297.
17. Demirer, T.; Buckner, C. D.; Appelbaum, F. R.; Bensinger, W. I.; Sanders, J.; Lambert, K.; Clift, R.; Fefer, A.; Storb, R.; Slattery, J. T. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant. 1996, 17, 491-495.
18. Demirer, T.; Buckner, C. D.; Appelbaum, F. R.; Lambert, K.; Bensinger, W. I.; Clift, R.; Storb, R.; Slattery, J. T. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant. 1996, 17, 341-346.
19. Lippman, M. E.; Sorace, R. A.; Bagley, C. S.; Danforth, D. W., Jr.; Lichter, A.; Wesley, M. N. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr. 1986, 153-159.
20. Goncalves, A.; Braud, A. C.; Viret, F.; Tarpin, C.; Charaffe-Jauffret, E.; Jacquemier, J.; Maraninchi, D.; Viens, P. High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study. Anticancer Res. 2005, 25, 663-667.
21. Filipits, M.; Pohl, G.; Rudas, M.; Dietze, O.; Lax, S.; Grill, R.; Pirker, R.; Zielinski, C. C.; Hausmaninger, H.; Kubista, E.; Samonigg, H.; Jakesz, R. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 2005, 23, 1161-1168.
22. Chrystal, K.; Cheong, K.; Harper, P. Chemotherapy of small cell lung cancer: state of the art. Curr. Opin. Oncol. 2004, 16, 136-140.
23. Hobdy, E. M.; Kraut, E.; Masters, G.; Blum, K.; McKeon, A.; Byrd, B.; Davies, M.; Beaulieu, N.; Murren, J. R. A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer. Cancer Biol. Ther. 2004, 3, 89-93.
24. Escalon, M. P.; Liu, N. S.; Yang, Y.; Hess, M.; Walker, P. L.; Smith, T. L.; Dang, N. H. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer 2005, 103, 2091-2098.
25. Zinzani, P. L. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin. Oncol. 2005, 32, S4-10.
26. Kasamon, Y. L.; Jones, R. J.; Piantadosi, S.; Ambinder, R. F.; Abrams, R. A.; Borowitz, M. J.; Morrison, C.; Smith, B. D.; Flinn, I. W. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol. Blood Marrow Transplant 2005, 11, 93-100.
27. Nicolini, A.; Mancini, P.; Ferrari, P.; Anselmi, L.; Tartarelli, G.; Bonazzi, V.; Carpi, A.; Giardino, R. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed. Pharmacother. 2004, 58, 447-450.
28. Stiff, P. J.; Shpall, E. J.; Liu, P. Y.; Wilczynski, S. P.; Callander, N. S.; Scudder, S. A.; Jazieh, A. R.; Samlowski, W.; McCoy, J.; Alberts, D. S. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecol. Oncol. 2004, 94, 98-106.
29. Donato, M. L.; Aleman, A.; Champlin, R. E.; Saliba, R. M.; Wharton, J. T.; Burke, T. W.; Bodurka, D. C.; Bevers, M. W.; Levenback, C. F.; Wolf, J. K.; Bast, R. C.; Freedman, R. S.; Ippoliti, C.; Brewer, M.; Gajewski, J. L.; Gershenson, D. M. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2004, 33, 1219-1224.
30. Harper, P. Current clinical practices for ovarian cancers. Semin. Oncol. 2002, 29, 3-6.
31. Morgan, R. J.; Doroshow, J. H.; Leong, L.; Schriber, J.; Shibata, S.; Forman, S.; Hamasaki, V.; Margolin, K.; Somlo, G.; Alvarnas, J.; McNamara, M.; Longmate, J.; Raschko, J.; Chow, W.; Vasilev, S.; McGonigle, K.; Yen, Y. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplant. 2001, 28, 859-863.
32. Inoue, M.; Fujita, M.; Enomoto, T.; Tanizawa, O. Long-term follow-up of patients with advanced ovarian cancers treated with intermittent administration of combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Int. J. Gynecol. Cancer 1995, 5, 374-380.
33. Dimopoulos, M. A.; Hamilos, G.; Zomas, A.; Gika, D.; Efstathiou, E.; Grigoraki, V.; Poziopoulos, C.; Xilouri, I.; Zorzou, M. P.; Anagnostopoulos, N.; Anagnostopoulos, A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol. J. 2004, 5, 112-117.
34. Lundin, J.; Osterborg, A.; Bjorkholm, M.; Bjorkstrand, B.; Celsing, F.; Hjalmar, V.; Linder, O.; Luthman, M.; Merup, M.; Tidefelt, U.; Mellstedt, H. Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III. Hematol. J. 2003, 4, 248-252.
35. Bonadonna, G.; Valagussa, P.; Moliterni, A.; Zambetti, M.; Brambilla, C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 1995, 332, 901-906.
36. Colleoni, M.; Litman, H. J.; Castiglione-Gertsch, M.; Sauerbrei, W.; Gelber, R. D.; Bonetti, M.; Coates, A. S.; Schumacher, M.; Bastert, G.; Rudenstam, C. M.; Schmoor, C.; Lindtner, J.; Collins, J.; Thurlimann, B.; Holmberg, S. B.; Crivellari, D.; Beyerle, C.; Neumann, R. L.; Goldhirsch, A. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br. J. Cancer 2002, 86, 1705-1714.
37. Brodsky, R. A. High-dose cyclophosphamide for aplastic anemia and autoimmunity. Curr. Opin. Oncol. 2002, 14, 143-146.
38. Boal, J. H.; Williamson, M.; Boyd, V. L.; Ludeman, S. M.; Egan, W. 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: comparisons with phosphoramide mustard. J. Med. Chem. 1989, 32, 1768-1773.
39. Kamen, B. A.; Frenkel, E.; Colvin, O. M. Ifosfamide: should the honeymoon be over? J. Clin. Oncol. 1995, 13, 307-309.
40. Smith, I. E.; Perren, T. J.; Ashley, S. A.; Woodiwiss, J.; Forgeson, G. V.; Yarnold, J. R.; Ford, H. T. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. J. Clin. Oncol. 1990, 8, 899-905.
41. Bourgeois, H.; Billiart, I.; Chabrun, V.; Chieze, S.; Lemerre, D.; Germain, T.; Ferrand, V.; Meurice, J. C.; Daban, A.; Tourani, J. M. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma. Am. J. Clin. Oncol. 2004, 27, 89-95.
42. Lorigan, P.; Woll, P. J.; O'Brien, M. E.; Ashcroft, L. F.; Sampson, M. R.; Thatcher, N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J. Natl. Cancer Inst. 2005, 97, 666-674.
43. Masters, G. A.; Hoffman, P. C.; Drinkard, L. C.; Samuels, B. L.; Golomb, H. M.; Vokes, E. E. A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung. Semin. Oncol. 1998, 25, 8-14.
44. Seo, J. H.; Whang, Y. M.; Kim, B. S.; Choi, C. W.; Shin, S. W.; Kim, Y. H.; Kim, J. S.; Goo, B. H. A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma. Cancer 2002, 94, 1925-1930.
45. Sorio, R.; Lombardi, D.; Spazzapan, S.; La Mura, N.; Tabaro, G.; Veronesi, A. Ifosfamide in advanced/disseminated breast cancer. Oncology 2003, 65(Suppl 2), 55-58.
46. Kosmas, C.; Tsavaris, N.; Malamos, N.; Stavroyianni, N.; Gregoriou, A.; Rokana, S.; Polyzos, A. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Br. J. Cancer 2003, 88, 1168-1174.
47. Gonzalez-Martin, A.; Crespo, C.; Garcia-Lopez, J. L.; Pedraza, M.; Garrido, P.; Lastra, E.; Moyano, A. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. Gynecol. Oncol. 2002, 84, 368-373.
48. Papadimitriou, C. A.; Kouroussis, C.; Moulopoulos, L. A.; Vlahos, G.; Rodolakis, A.; Kiamouris, C.; Diakomanolis, E.; Gika, D.; Michalas, S.; Dimopoulos, M. A. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer. Cancer 2001, 92, 1856-1863.
49. Calabro, F.; Sternberg, C. N. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J. Urol. 2002, 20, 158-166.
50. Hussain, S. A.; James, N. D. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol. 2003, 4, 489-497.
51. Patton, S. E.; Hall, M. C.; Ozen, H. Bladder cancer. Curr. Opin. Oncol. 2002, 14, 265-272.
52. Buda, A.; Dell'Anna, T.; Signorelli, M.; Mangioni, C. Role of ifosfamide in cervical cancer: an overview. Oncology 2003, 65(Suppl 2), 63-66.
53. Berrak, S. G.; Pearson, M.; Berberoglu, S.; Ilhan, I. E.; Jaffe, N. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr. Blood Cancer 2005, 44, 215-219.
54. Kim, D. W.; Jo, Y. H.; Kim, J. H.; Wu, H. G.; Rhee, C. S.; Lee, C. H.; Kim, T. Y.; Heo, D. S.; Bang, Y. J.; Kim, N. K. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 2004, 101, 2257-2260.
55. Donfrancesco, A.; Jenkner, A.; Castellano, A.; Ilari, I.; Milano, G. M.; De Sio, L.; Cozza, R.; Fidani, P.; Deb, G.; De Laurentis, C.; Inserra, A.; Dominici, C. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr. Suppl. 2004, 93, 6-11.
56. Thomson, B.; Park, J. R.; Felgenhauer, J.; Meshinchi, S.; Holcenberg, J.; Geyer, J. R.; Avramis, V.; Douglas, J. G.; Loken, M. R.; Hawkins, D. S. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Pediatr. Blood Cancer 2004, 43, 571-579.
57. Graziano, S. L.; Valone, F. H.; Herndon, J. E., 2nd; Crawford, J.; Richards, F., 2nd; Rege, V. B.; Clamon, G.; Green, M. R. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 1996, 14, 315-329.
58. Arland, M.; Leuner, S.; Lange, S.; Bartsch, R.; Kahl, C.; Florschutz, A.; Franke, A.; Hoffkes, H. G. Ifosamide, epirubicin and granulocyte colony-stimulating factor: a regimen for successful mobilization of peripheral blood progenitor cells in patients with multiple myeloma. Hematol. Oncol. 2001, 19, 59-66.
59. Biagi, J. J.; Herbert, K. E.; Smith, C.; Abdi, E.; Leahy, M.; Falkson, C.; Wolf, M.; Januszewicz, H.; Seymour, J. F.; Richards, K.; Matthews, J. P.; Dale, B.; Prince, H. M. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leuk. Lymphoma 2005, 46, 197-206.
60. Mayer, J.; Vasova, I.; Koristek, Z.; Navratil, M.; Klabusay, M.; Doubek, M.; Vorlicek, J.; Cernilova, I.; Vodvarka, P.; Petrakova, K. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Eur. J. Haematol. Suppl. 2001, 21-27.
61. Kohn, K. W.; Hartley, J. A.; Mattes, W. B. Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards. Nucleic Acids Res. 1987, 15, 10531-10549.
62. Springer, J. B.; Colvin, M. E.; Colvin, O. M.; Ludeman, S. M. Isophosphoramide mustard and its mechanism of bisalkylation. J. Org. Chem. 1998, 63, 7218-7222.
63. Friedman, H. S.; Pegg, A. E.; Johnson, S. P.; Loktionova, N. A.; Dolan, M. E.; Modrich, P.; Moschel, R. C.; Struck, R.; Brent, T. P.; Ludeman, S.; Bullock, N.; Kilborn, C.; Keir, S.; Dong, Q.; Bigner, D. D.; Colvin, O. M. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. Cancer Chemother. Pharmacol. 1999, 43, 80-85.
64. O'Connor, P. M.; Wassermann, K.; Sarang, M.; Magrath, I.; Bohr, V. A.; Kohn, K. W. Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res. 1991, 51, 6550-6557.
65. Bhatia, U.; Danishefsky, K.; Traganos, F.; Darzynkiewicz, Z. Induction of apoptosis and cell cycle-specific change in expression of p53 in normal lymphocytes and MOLT-4 leukemic cells by nitrogen mustard. Clin. Cancer Res. 1995, 1, 873-880.
66. Crook, T. R.; Souhami, R. L.; McLean, A. E. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res. 1986, 46, 5029-5034.
67. Schwartz, P. S.; Waxman, D. J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol. 2001, 60, 1268-1279.
68. Bruggemann, S. K.; Kisro, J.; Wagner, T. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res. 1997, 57, 2676-2680.
69. Zhang, J.; Tian, Q.; Chan, S. Y.; Duan, W.; Li, S. C.; Zhu, Y. Z.; Zhou, S. F. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab. Rev. 2005, 37, 1-93.
70. Sladek, N. E. Metabolism of oxazaphosphorines. Pharmacol. Ther. 1988, 37, 301-355.
71. Colvin, M.; Brundrett, R. B.; Kan, M. N.; Jardine, I.; Fenselau, C. Alkylating properties of phosphoramide mustard. Cancer Res. 1976, 36, 1121-1126.
72. Chang, T. K.; Weber, G. F.; Crespi, C. L.; Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993, 53, 5629-5637.
73. Ren, S.; Yang, J. S.; Kalhorn, T. F.; Slattery, J. T. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res. 1997, 57, 4229-4235.
74. Huang, Z.; Roy, P.; Waxman, D. J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 2000, 59, 961-972.
75. Roy, P.; Yu, L. J.; Crespi, C. L.; Waxman, D. J. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab. Dispos. 1999, 27, 655-666.
76. Ataya, K.; Pydyn, E.; Young, J.; Struck, R. The uptake and metabolism of cyclophosphamide by the ovary. Sel. Cancer Ther. 1990, 6, 83-92.
77. Fenselau, C.; Kan, M. N.; Rao, S. S.; Myles, A.; Friedman, O. M.; Colvin, M. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res. 1977, 37, 2538-2543.
78. Hohorst, H. J.; Draeger, U.; Peter, G.; Voelcker, G. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity. Cancer Treat. Rep. 1976, 60, 309-315.
79. Colvin, O. M. An overview of cyclophosphamide development and clinical applications. Curr. Pharm. Des. 1999, 5, 555-560.
80. Gurtoo, H. L.; Hipkens, J. H.; Sharma, S. D. Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide. Cancer Res. 1981, 41, 3584-3591.
81. DeLeve, L. D. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996, 24, 830-837.
82. Struck, R. F.; Kirk, M. C.; Witt, M. H.; Laster, W. R., Jr. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed. Mass Spectrom. 1975, 2, 46-52.
83. Dockham, P. A.; Sreerama, L.; Sladek, N. E. Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines. Drug Metab. Dispos. 1997, 25, 1436-1441.
84. von Eitzen, U.; Meier-Tackmann, D.; Agarwal, D. P.; Goedde, H. W. Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes. Cancer Lett. 1994, 76, 45-49.
85. Sladek, N. E.; Dockham, P. A.; Lee, M. O. Human and mouse hepatic aldehyde dehydrogenases important in the biotransformation of cyclophosphamide and the retinoids. Adv. Exp. Med. Biol. 1991, 284, 97-104.
86. Manthey, C. L.; Sladek, N. E. Aldehyde dehydrogenase-catalyzed bioinactivation of cyclophosphamide. Prog. Clin. Biol. Res. 1989, 290, 49-63.
87. Hipkens, J. H.; Struck, R. F.; Gurtoo, H. L. Role of aldehyde dehydrogenase in the metabolism-dependent biological activity of cyclophosphamide. Cancer Res. 1981, 41, 3571-3583.
88. Domeyer, B. E.; Sladek, N. E. Metabolism of 4-hydroxycyclophosphamide/ aldophosphamide in vitro. Biochem. Pharmacol. 1980, 29, 2903-2912.
89. Cox, P. J.; Phillips, B. J.; Thomas, P. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes. Cancer Treat. Rep. 1976, 60, 321-326.
90. Yule, S. M.; Boddy, A. V.; Cole, M.; Price, L.; Wyllie, R.; Tasso, M. J.; Pearson, A. D.; Idle, J. R. Cyclophosphamide metabolism in children. Cancer Res. 1995, 55, 803-809.
91. Yule, S. M.; Price, L.; McMahon, A. D.; Pearson, A. D.; Boddy, A. V. Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clin. Cancer Res. 2004, 10, 455-460.
92. Moreb, J. S.; Gabr, A.; Vartikar, G. R.; Gowda, S.; Zucali, J. R.; Mohuczy, D. Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J. Pharmacol. Exp. Ther. 2005, 312, 339-345.
93. Joqueviel, C.; Martino, R.; Gilard, V.; Malet-Martino, M.; Canal, P.; Niemeyer, U. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Drug Metab. Dispos. 1998, 26, 418-428.
94. Lelieveld, P.; van Putten, L. M. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271). Cancer Treat. Rep. 1976, 60, 373-379.
95. Boddy, A. V.; Furtun, Y.; Sardas, S.; Sardas, O.; Idle, J. R. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J. Natl. Cancer Inst. 1992, 84, 1744-1748.
96. Jarman, M. Formation of 4-ketocyclophosphamide by the oxidation of cyclophosphamide with KMnO4. Experientia 1973, 29, 812-814.
97. Hohorst, H. J.; Ziemann, A.; Brock, N. 4-Ketocyclophosphamide, a metabolite of cyclophosphamide. Formation, chemical and biological properties. Arzneimittelforschung 1971, 21, 1254-1257.
98. Dirven, H. A.; van Ommen, B.; van Bladeren, P. J. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 1994, 54, 6215-6220.
99. Dirven, H. A.; Venekamp, J. C.; van Ommen, B.; van Bladeren, P. J. The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy. Chem. Biol. Interact. 1994, 93, 185-196.
100. Allen, L. M.; Creaven, P. J. Pharmacokinetics of ifosfamide. Clin. Pharmacol. Ther. 1975, 17, 492-498.
101. Allen, L. M.; Creaven, P. J.; Nelson, R. L. Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat. Rep. 1976, 60, 451-458.
102. Boddy, A. V.; Yule, S. M.; Wyllie, R.; Price, L.; Pearson, A. D.; Idle, J. R. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res. 1993, 53, 3758-3764.
103. Boddy, A. V.; Proctor, M.; Simmonds, D.; Lind, M. J.; Idle, J. R. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur. J. Cancer 1995, 31, 69-76.
104. Boddy, A. V.; Yule, S. M. Metabolism and pharmacokinetics of oxazaphosphorines. Clin. Pharmacokinet. 2000, 38, 291-304.
105. Furlanut, M.; Franceschi, L. Pharmacology of ifosfamide. Oncology 2003, 65 Suppl 2, 2-6.
106. Highley, M. S.; Momerency, G.; Van Cauwenberghe, K.; Van Oosterom, A. T.; de Bruijn, E. A.; Maes, R. A.; Blake, P.; Mansi, J.; Harper, P. G. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans. Drug Metab. Dispos. 1995, 23, 433-437.
107. Hill, D. L.; Laster, W. R., Jr.; Kirk, M. C.; el-Dareer, S.; Struck, R. F. Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphor ine 2-oxide) and production of a toxic iphosphamide metabolite. Cancer Res. 1973, 33, 1016-1022.
108. Boddy, A. V.; English, M.; Pearson, A. D.; Idle, J. R.; Skinner, R. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur. J. Cancer 1996, 32A, 1179-1184.
109. Walker, D.; Flinois, J. P.; Monkman, S. C.; Beloc, C.; Boddy, A. V.; Cholerton, S.; Daly, A. K.; Lind, M. J.; Pearson, A. D.; Beaune, P. H.; Idle, J. R. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol. 1994, 47, 1157-1163.
110. McCune, J. S.; Risler, L. J.; Phillips, B. R.; Thummel, K. E.; Blough, D.; Shen, D. D. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab. Dispos. 2005, 33, 1074-1081
111. Borner, K.; Kisro, J.; Bruggemann, S. K.; Hagenah, W.; Peters, S. O.; Wagner, T. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Drug Metab. Dispos. 2000, 28, 573-576.
112. Brade, W. P.; Herdrich, K.; Varini, M. Ifosfamide - pharmacology, safety and therapeutic potential. Cancer Treat. Rev. 1985, 12, 1-47.
113. Carlson, L.; Goren, M. P.; Bush, D. A.; Griener, J. C.; Quigley, R.; Tkaczewski, I.; Kamen, B. A.; Weitman, S. D. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor. Cancer Chemother. Pharmacol. 1998, 41, 140-146.
114. Cerny, T.; Leyvraz, S.; von Briel, T.; Kupfer, A.; Schaad, R.; Schmitz, S. F.; Honegger, P.; Sessa, C.; Brunner, J.; Boddy, A. V. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 1999, 10, 1087-1094.
115. Goren, M. P.; Wright, R. K.; Pratt, C. B.; Pell, F. E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986, 2, 1219-1220.
116. DiMaggio, J. R.; Brown, R.; Baile, W. F.; Schapira, D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994, 73, 1509-1514.
117. Curtin, J. P.; Koonings, P. P.; Gutierrez, M.; Schlaerth, J. B.; Morrow, C. P. Ifosfamide-induced neurotoxicity. Gynecol. Oncol. 1991, 42, 193-196; discussion 191-192.
118. Springate, J. E. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J. Appl. Toxicol. 1997, 17, 75-79.
119. Springate, J.; Zamlauski-Tucker, M. J.; Lu, H.; Chan, K. K. Renal clearance of ifosfamide. Drug Metab. Dispos. 1997, 25, 1081-1082.
120. Skinner, R.; Sharkey, I. M.; Pearson, A. D.; Craft, A. W. Ifosfamide, mesna, and nephrotoxicity in children. J. Clin. Oncol. 1993, 11, 173-190.
121. Woodland, C.; Ito, S.; Granvil, C. P.; Wainer, I. W.; Klein, J.; Koren, G. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci. 2000, 68, 109-117.
122. Spengler, S. J.; Singer, B. Formation of interstrand cross-links in chloroacetaldehyde-treated DNA demonstrated by ethidium bromide fluorescence. Cancer Res. 1988, 48, 4804-4806.
123. Sood, C.; O'Brien, P. J. Molecular mechanisms of chloroacetaldehyde- induced cytotoxicity in isolated rat hepatocytes. Biochem. Pharmacol. 1993, 46, 1621-1626.
124. Brock, N.; Stekar, J.; Pohl, J.; Niemeyer, U.; Scheffler, G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 1979, 29, 659-661.
125. Dumez, H.; Reinhart, W. H.; Guetens, G.; de Bruijn, E. A. Human red blood cells: rheological aspects, uptake, and release of cytotoxic drugs. Crit. Rev. Clin. Lab. Sci. 2004, 41, 159-188.
126. Highley, M. S.; Schrijvers, D.; Van Oosterom, A. T.; Harper, P. G.; Momerency, G.; Van Cauwenberghe, K.; Maes, R. A.; De Bruijn, E. A.; Edelstein, M. B. Activated oxazaphosphorines are transported predominantly by erythrocytes. Ann. Oncol. 1997, 8, 1139-1144.
127. Momerency, G.; Van Cauwenberghe, K.; Highley, M. S.; Harper, P. G.; Van Oosterom, A. T.; De Bruijn, E. A. Partitioning of ifosfamide and its metabolites between red blood cells and plasma. J. Pharm. Sci. 1996, 85, 262-265.
128. Highley, M. S.; Harper, P. G.; Slee, P. H.; DeBruijn, E. Preferential location of circulating activated cyclophosphamide within the erythrocyte. Int. J. Cancer 1996, 65, 711-712.
129. Highley, M. S.; De Bruijn, E. A. Erythrocytes and the transport of drugs and endogenous compounds. Pharm. Res. 1996, 13, 186-195.
130. Struck, R. F.; Dykes, D. J.; Corbett, T. H.; Suling, W. J.; Trader, M. W. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide. Br. J. Cancer 1983, 47, 15-26.
131. Boyd, V. L.; Robbins, J. D.; Egan, W.; Ludeman, S. M. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites. J. Med. Chem. 1986, 29, 1206-1210.
132. Burger, H.; Foekens, J. A.; Look, M. P.; Meijer-van Gelder, M. E.; Klijn, J. G.; Wiemer, E. A.; Stoter, G.; Nooter, K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 2003, 9, 827-836.
133. Tian, Q.; Zhang, J.; Tan, T. M.; Chan, E.; Duan, W.; Chan, S. Y.; Boelsterli, U. A.; Ho, P. C.; Yang, H.; Bian, J. S.; Huang, M.; Zhu, Y. Z.; Xiong, W.; Li, X.; Zhou, S. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res. 2005, 22, 1837-1853.
134. Borst, P.; Elferink, R. O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002, 71, 537-592.
135. Tian, Q.; Zhang, J.; Chan, E.; Duan, W.; Zhou, S. F. Multidrug resistance proteins (MRPs) and implication in drug development. Drug Dev. Res. 2005, 51, 1-18.
136. Qiu, R.; Kalhorn, T. F.; Slattery, J. T. ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat. J . Pharmacol. Exp. Ther. 2004, 308, 1204-1212.
137. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. The multidrug resistance protein family. Biochim. Biophys. Acta. 1999, 1461, 347-357.
138. Konig, J.; Nies, A. T.; Cui, Y.; Leier, I.; Keppler, D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity and MRP2-mediated drug resistance. Biochim. Biophys. Acta. 1999, 1461, 377-394.
139. Machida, I.; Wakusawa, S.; Sanae, F.; Hayashi, H.; Kusakabe, A.; Ninomiya, H.; Yano, M.; Yoshioka, K. Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan. J. Gastroenterol. 2005, 40, 366-370.
140. Toh, S.; Wada, M.; Uchiumi, T.; Inokuchi, A.; Makino, Y.; Horie, Y.; Adachi, Y.; Sakisaka, S.; Kuwano, M. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 1999, 64, 739-746.
141. Gheuens, E.; Slee, P. H.; de Bruijn, E. A. Bioavailability of cyclophosphamide in the CMF regimen. Onkologie 1990, 13, 203-206.
142. De Bruijn, E. A.; Slee, P. H.; Van Oosterom, A. T.; Lameijer, D. W.; Roozendaal, K. J.; Tjaden, U. R. Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. Pharm. Weekbl. Sci. 1988, 10, 200-206.
143. Wagner, T.; Fenneberg, K. Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations. Arzneimittelforschung 1984, 34, 313-316.
144. Stewart, D. J.; Morgan, L. R., Jr.; Verma, S.; Maroun, J. A.; Thibault, M. Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study. Invest. New Drugs 1995, 13, 99-107.
145. Wagner, T.; Fenneberg, K. Bioavailability of cyclophosphamide from oral formulations. Eur. J. Clin. Pharmacol. 1984, 26, 269-270.
146. Matthias, M.; Sohr, R.; Preiss, R.; Brockmann, B. [Bioavailability of cyclophosphamide following oral administration in high doses]. Onkologie 1984, 7, 48-49.
147. Kurowski, V.; Cerny, T.; Kupfer, A.; Wagner, T. Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J. Cancer Res. Clin. Oncol. 1991, 117(Suppl 4), S148-S153.
148. Cerny, T.; Margison, J. M.; Thatcher, N.; Wilkinson, P. M. Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother. Pharmacol. 1986, 18, 261-264.
149. Aeschlimann, C.; Kupfer, A.; Schefer, H.; Cerny, T. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab. Dispos. 1998, 26, 883-890.
150. Manegold, C.; Drings, P.; Pawinski, A.; Lentz, M. A.; van Glabbeke, M.; van Zandwijk, N.; Bachmann, P.; Schnaars, Y.; Skacel, Z.; Zatloukal, P.; Dolensky, J.; Jackevicius, A.; Petruzelka, L.; Giaccone, G. Oral
151. Manegold, C.; Bischoff, H.; Fischer, J. R.; Lochner, S.; Peukert, M.; Schmahl, A.; Drings, P. Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer. Ann. Oncol. 1992, 3, 723-726.
152. Lind, M. J.; Margison, J. M.; Cerny, T.; Thatcher, N.; Wilkinson, P. M. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res. 1989, 49, 753-757.
153. McNiel, N. O.; Morgan, L. R., Jr. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. Int. J. Clin. Pharmacol. Ther. Toxicol. 1981, 19, 490-493.
154. Kaijser, G. P.; Beijnen, J. H.; Bult, A.; Underberg, W. J. Ifosfamide metabolism and pharmacokinetics (review). Anticancer Res. 1994, 14, 517-531.
155. Goren, M. P. Oral administration of mesna with ifosfamide. Semin. Oncol. 1996, 23, 91-96.
156. Wagner, T.; Drings, P. Pharmacokinetics and bioavailability of oral ifosfamide. Arzneimittelforschung 1986, 36, 878-880.
157. Moore, M. J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 1991, 20, 194-208.
158. Kaijser, G. P.; De Kraker, J.; Bult, A.; Underberg, W. J.; Beijnen, J. H. Pharmacokinetics of ifosfamide and some metabolites in children. Anticancer Res. 1998, 18, 1941-1949.
159. Yule, S. M.; Price, L.; Pearson, A. D.; Boddy, A. V. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin. Cancer Res. 1997, 3, 1985-1992.
160. Fasola, G.; Lo Greco, P.; Calori, E.; Zilli, M.; Verlicchi, F.; Motta, M. R.; Ricci, P.; Baccarani, M.; Tura, S. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation. Haematologica 1991, 76, 120-125.
161. Juma, F. D.; Rogers, H. J.; Trounce, J. R. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br. J. Clin. Pharmacol. 1979, 8, 209-217.
162. Dooley, J. S.; James, C. A.; Rogers, H. J.; Stuart-Harris, R. Biliary elimination of cyclophosphamide in man. Cancer Chemother. Pharmacol. 1982, 9, 26-29.
163. de Jonge, M. E.; Huitema, A. D.; Rodenhuis, S.; Beijnen, J. H. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 2005, 44, 1135-1164.
164. Kerbusch, T.; de Kraker, J.; Keizer, H. J.; van Putten, J. W.; Groen, H. J.; Jansen, R. L.; Schellens, J. H.; Beijnen, J. H. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin. Pharmacokinet. 2001, 40, 41-62.
165. Moore, M. J.; Erlichman, C.; Thiessen, J. J.; Bunting, P. S.; Hardy, R.; Kerr, I.; Soldin, S. Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother. Pharmacol. 1994, 33, 472-476.
166. Yule, S. M.; Boddy, A. V.; Cole, M.; Price, L.; Wyllie, R.; Tasso, M. J.; Pearson, A. D.; Idle, J. R. Cyclophosphamide pharmacokinetics in children. Br. J. Clin. Pharmacol. 1996, 41, 13-19.
167. Ren, S.; Kalhorn, T. F.; McDonald, G. B.; Anasetti, C.; Appelbaum, F. R.; Slattery, J. T. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin. Pharmacol. Ther. 1998, 64, 289-301.
168. Chang, T. K.; Yu, L.; Goldstein, J. A.; Waxman, D. J. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997, 7, 211-221.
169. Roy, P.; Tretyakov, O.; Wright, J.; Waxman, D. J. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab. Dispos. 1999, 27, 1309-1318.
170. Stresser, D. M.; Kupfer, D. Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab. Dispos. 1999, 27, 517-525.
171. Code, E. L.; Crespi, C. L.; Penman, B. W.; Gonzalez, F. J.; Chang, T. K.; Waxman, D. J. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 1997, 25, 985-993.
172. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
173. Watkins, P. B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994, 4, 171-184.
174. Thummel, K. E.; Shen, D. D.; Podoll, T. D.; Kunze, K. L.; Trager, W. F.; Hartwell, P. S.; Raisys, V. A.; Marsh, C. L.; McVicar, J. P.; Barr, D. M.; Perkins, J. D. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 1994, 271, 549-556.
175. Kharasch, E. D.; Hoffer, C.; Walker, A.; Sheffels, P. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin. Pharmacol. Ther. 2003, 73, 199-208.
176. Gibson, G. G.; Plant, N. J.; Swales, K. E.; Ayrton, A.; El-Sankary, W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002, 32, 165-206.
177. Andersson, B. S.; Mroue, M.; Britten, R. A.; Farquhar, D.; Murray, D. Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line. Acta Oncol. 1995, 34, 247-251.
178. Giai, M.; Biglia, N.; Sismondi, P. Chemoresistance in breast tumors. Eur. J. Gynaecol. Oncol. 1991, 12, 359-373.
179. Ludeman, S. M.; Gamcsik, M. P. Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity? Cancer Treat. Res. 2002, 112, 177-197.
180. Chen, G.; Teicher, B. A.; Frei, E., 3rd. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype. Cancer Biochem. Biophys. 1998, 16, 139-155.
181. Vyas, S.; Hidalgo, G.; Baqi, N.; Von Gizyki, H.; Singh, A. Outcome in African-American children of neuropsychiatric lupus and lupus nephritis. Pediatr. Nephrol. 2002, 17, 45-49.
182. Bakir, A. A.; Levy, P. S.; Dunea, G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am. J. Kidney Dis. 1994, 24, 159-171.
183. Dooley, M. A.; Hogan, S.; Jennette, C.; Falk, R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997, 51, 1188-1195.
184. Dirven, H. A.; Megens, L.; Oudshoorn, M. J.; Dingemanse, M. A.; van Ommen, B.; van Bladeren, P. J. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem. Res. Toxicol. 1995, 8, 979-986.
185. Bunting, K. D.; Townsend, A. J. Dependence of aldehyde dehydrogenase-mediated oxazaphosphorine resistance on soluble thiols: importance of thiol interactions with the secondary metabolite acrolein. Biochem. Pharmacol. 1998, 56, 31-39.
186. Crook, T. R.; Souhami, R. L.; Whyman, G. D.; McLean, A. E. Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide. Cancer Res. 1986, 46, 5035-5038.
187. Gurtoo, H. L.; Marinello, A. J.; Berrigan, M. J.; Bansal, S. K.; Paul, B.; Pavelic, Z. P.; Struck, R. F. Effect of thiols on toxicity and carcinostatic activity of cyclophosphamide. Semin. Oncol. 1983, 10, 35-45.
188. Richardson, M. E.; Siemann, D. W. DNA damage in cyclophosphamide- resistant tumor cells: the role of glutathione. Cancer Res. 1995, 55, 1691-1695.
189. Chen, G.; Waxman, D. J. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem. Pharmacol. 1995, 49, 1691-1701.
190. Mulders, T. M.; Keizer; Ouwerkerk, J.; van der Velde, E. A.; Breimer, D. D.; Mulder, G. J. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Clin. Cancer Res. 1995, 1, 1525-1536.
191. Tanner, B.; Hengstler, J. G.; Dietrich, B.; Henrich, M.; Steinberg, P.; Weikel, W.; Meinert, R.; Kaina, B.; Oesch, F.; Knapstein, P. G. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol. Oncol. 1997, 65, 54-62.
192. Morrow, C. S.; Smitherman, P. K.; Townsend, A. J. Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem. Pharmacol. 1998, 56, 1013-1021.
193. Vasiliou, V.; Pappa, A.; Estey, T. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab. Rev. 2004, 36, 279-299.
194. Sophos, N. A.; Vasiliou, V. Aldehyde dehydrogenase gene superfamily: the 2002 update. Chem. Biol. Interact. 2003, 143-144, 5-22.
195. Sophos, N. A.; Pappa, A.; Ziegler, T. L.; Vasiliou, V. Aldehyde dehydrogenase gene superfamily: the 2000 update. Chem. Biol. Interact. 2001, 130-132, 323-337.
196. Yoshida, A.; Rzhetsky, A.; Hsu, L. C.; Chang, C. Human aldehyde dehydrogenase gene family. Eur. J. Biochem. 1998, 251, 549-557.
197. Hsu, L. C.; Chang, W. C.; Yoshida, A. Human aldehyde dehydrogenase genes, ALDH7 and ALDH8: genomic organization and gene structure comparison. Gene 1997, 189, 89-94.
198. Vasiliou, V. Aldehyde dehydrogenase genes. Adv. Exp. Med. Biol. 1997, 414, 595-600.
199. Yoshida, A. Molecular genetics of human aldehyde dehydrogenase. Pharmacogenetics 1992, 2, 139-147.
200. Agarwal, D. P.; von Eitzen, U.; Meier-Tackmann, D.; Goedde, H. W. Metabolism of cyclophosphamide by aldehyde dehydrogenases. Adv. Exp. Med. Biol. 1995, 372, 115-122.
201. Maki, P. A.; Sladek, N. E. Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide. Biochem. Pharmacol. 1993, 45, 231-239.
202. Sreerama, L.; Sladek, N. E. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem. Pharmacol. 1993, 45, 2487-2505.
203. Sreerama, L.; Sladek, N. E. Identification of the class-3 aldehyde dehydrogenases present in human MCF-7/0 breast adenocarcinoma cells and normal human breast tissue. Biochem. Pharmacol. 1994, 48, 617-620.
204. Magni, M.; Shammah, S.; Schiro, R.; Mellado, W.; Dalla-Favera, R.; Gianni, A. M. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996, 87, 1097-1103.
205. Takebe, N.; Zhao, S. C.; Adhikari, D.; Mineishi, S.; Sadelain, M.; Hilton, J.; Colvin, M.; Banerjee, D.; Bertino, J. R. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol. Ther. 2001, 3, 88-96.
206. Sladek, N. E. Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s). Cancer Treat. Res. 2002, 112, 161-175.
207. Quash, G.; Fournet, G.; Chantepie, J.; Gore, J.; Ardiet, C.; Ardail, D.; Michal, Y.; Reichert, U. Novel competitive irreversible inhibitors of aldehyde dehydrogenase (ALDH1): restoration of chemosensitivity of L1210 cells overexpressing ALDH1 and induction of apoptosis in BAF(3) cells overexpressing bcl(2). Biochem. Pharmacol. 2002, 64, 1279-1292.
208. Tsukamoto, N.; Chen, J.; Yoshida, A. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Blood Cells Mol. Dis. 1998, 24, 231-238.
209. Moreb, J. S.; Schweder, M.; Gray, B.; Zucali, J.; Zori, R. In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4- hydroperoxycyclophosphamide. Hum. Gene Ther. 1998, 9, 611-619.
210. Bunting, K. D.; Townsend, A. J. Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J. Biol. Chem. 1996, 271, 11891-11896.
211. Bunting, K. D.; Townsend, A. J. De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand crosslinking and lethality. J. Biol. Chem. 1996, 271, 11884-11890.
212. Andersson, B. S.; Mroue, M.; Britten, R. A.; Murray, D. The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues. Cancer Res. 1994, 54, 5394-5400.
213. de Groot, C. J.; Martens, A. C.; Hagenbeek, A. Aldehyde dehydrogenase involvement in a variant of the brown Norway rat acute myelocytic leukaemia (BNML) that acquired cyclophosphamide resistance in vivo. Eur. J. Cancer 1994, 30A, 2137-2143.
214. Yoshida, A.; Dave, V.; Han, H.; Scanlon, K. J. Enhanced transcription of the cytosolic ALDH gene in cyclophosphamide resistant human carcinoma cells. Adv. Exp. Med. Biol. 1993, 328, 63-72.
215. Friedman, H. S.; Colvin, O. M.; Kaufmann, S. H.; Ludeman, S. M.; Bullock, N.; Bigner, D. D.; Griffith, O. W. Cyclophosphamide resistance in medulloblastoma. Cancer Res. 1992, 52, 5373-5378.
216. Moreb, J.; Zucali, J. R.; Zhang, Y.; Colvin, M. O.; Gross, M. A. Role of aldehyde dehydrogenase in the protection of hematopoietic progenitor cells from 4-hydroperoxycyclophosphamide by interleukin 1 beta and tumor necrosis factor. Cancer Res. 1992, 52, 1770-1774.
217. Radin, A. I.; Zhoa, X. L.; Woo, T. H.; Colvin, O. M.; Hilton, J. Structure and expression of the cytosolic aldehyde dehydrogenase gene in cyclophosphamide-resistant murine leukemia L1210 cells. Biochem. Pharmacol. 1991, 42, 1933-1939.
218. Parsons, P. G.; Lean, J.; Kable, E. P.; Favier, D.; Khoo, S. K.; Hurst, T.; Holmes, R. S.; Bellet, A. J. Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines. Biochem. Pharmacol. 1990, 40, 2641-2649.
219. Koelling, T. M.; Yeager, A. M.; Hilton, J.; Haynie, D. T.; Wiley, J. M. Development and characterization of a cyclophosphamide-resistant subline of acute myeloid leukemia in the Lewis x Brown Norway hybrid rat. Blood 1990, 76, 1209-1213.
220. Kastan, M. B.; Schlaffer, E.; Russo, J. E.; Colvin, O. M.; Civin, C. I.; Hilton, J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990, 75, 1947-1950.
221. Russo, J. E.; Hilton, J. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res. 1988, 48, 2963-2968.
222. Sahovic, E. A.; Colvin, M.; Hilton, J.; Ogawa, M. Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Cancer Res. 1988, 48, 1223-1226.
223. Colvin, M.; Russo, J. E.; Hilton, J.; Dulik, D. M.; Fenselau, C. Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues. Adv. Enzyme Regul. 1988, 27, 211-221.
224. Hilton, J. Deoxyribonucleic acid crosslinking by 4- hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells. Biochem. Pharmacol. 1984, 33, 1867-1872.
225. Kohn, F. R.; Sladek, N. E. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557). Biochem. Pharmacol. 1987, 36, 2805-2811.
226. Sladek, N. E.; Landkamer, G. J. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and crosslinking agent-resistant P388 cell lines. Cancer Res. 1985, 45, 1549-1555.
227. Hilton, J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res. 1984, 44, 5156-5160.
228. Sreerama, L.; Rekha, G. K.; Sladek, N. E. Phenolic antioxidant-induced overexpression of class-3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance. Biochem. Pharmacol. 1995, 49, 669-75.
229. Rekha, G. K.; Sreerama, L.; Sladek, N. E. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem. Pharmacol. 1994, 48, 1943-1952.
230. Bunting, K. D.; Lindahl, R.; Townsend, A. J. Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J. Biol. Chem. 1994, 269, 23197-23203.
231. Hayes, J. D.; Judah, D. J.; Neal, G. E. Resistance to aflatoxin B1 is associated with the expression of a novel aldo-keto reductase which has catalytic activity towards a cytotoxic aldehyde-containing metabolite of the toxin. Cancer Res. 1993, 53, 3887-3894.
232. Lee, K. W.; Ko, B. C.; Jiang, Z.; Cao, D.; Chung, S. S. Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 2001, 12, 129-132.
233. Andersson, T.; Miners, J. O.; Veronese, M. E.; Birkett, D. J. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. 1994, 37, 597-604.
234. Dong, Q.; Bullock, N.; Ali-Osman, F.; Colvin, O. M.; Bigner, D. D.; Friedman, H. S. Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide- sensitive and -resistant medulloblastoma cell lines. Cancer Chemother. Pharmacol. 1996, 37, 242-246.
235. Friedman, H. S.; Johnson, S. P.; Colvin, O. M. Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines. Cancer Treat. Res. 2002, 112, 199-209.
236. Muller, M. R.; Buschfort, C.; Thomale, J.; Lensing, C.; Rajewsky, M. F.; Seeber, S. DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia. Clin. Cancer Res. 1997, 3, 2055-2061.
237. Mattern, J.; Eichhorn, U.; Kaina, B.; Volm, M. O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int. J. Cancer 1998, 77, 919-922.
238. Preuss, I.; Thust, R.; Kaina, B. Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int. J. Cancer 1996, 65, 506-512.
239. Cayre, A.; Penault-Llorca, F.; De Latour, M.; Rolhion, C.; Feillel, V.; Ferriere, J. P.; Kwiatkowski, F.; Finat-Duclos, F.; Verrelle, P. O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma. Int. J. Oncol. 2002, 21, 1125-1131.
240. Aebi, S.; Fink, D.; Gordon, R.; Kim, H. K.; Zheng, H.; Fink, J. L.; Howell, S. B. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res. 1997, 3, 1763-1767.
241. Andersson, B. S.; Sadeghi, T.; Siciliano, M. J.; Legerski, R.; Murray, D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother. Pharmacol. 1996, 38, 406-416.
242. Son, B. H.; Ahn, S. H.; Ko, C. D.; Ka, I. W.; Gong, G. Y.; Kim, J. C. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J. 2004, 10, 20-26.
243. Dole, M. G.; Jasty, R.; Cooper, M. J.; Thompson, C. B.; Nunez, G.; Castle, V. P. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 1995, 55, 2576-2582.
244. Domen, J.; Weissman, I. L. Hematopoietic stem cells and other hematopoietic cells show broad resistance to chemotherapeutic agents in vivo when overexpressing bcl-2. Exp. Hematol. 2003, 31, 631-639.
245. Yang, Q. F.; Sakurai, T.; Yoshimura, G.; Shan, L.; Suzuma, T.; Tamaki, T.; Umemura, T.; Kokawa, Y.; Nakamura, Y.; Nakamura, M.; Tang, W.; Utsunomiya, H.; Mori, I.; Kakudo, K. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res. Treat. 2000, 61, 211-216.
246. Wormhoudt, L. W.; Commandeur, J. N. M.; Vermeulen, N. P. E. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-Transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit. Rev. Toxicol. 1999, 29, 59-124.
247. Desta, Z.; Zhao, X.; Shin, J. G.; Flockhart, D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 2002, 41, 913-958.
248. Rodrigues, A. D.; Rushmore, T. H. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr. Drug. Metab. 2002, 3, 289-309.
249. Lee, C. R.; Goldstein, J. A.; Pieper, J. A. Cytochrome P4502C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 2002, 12, 251-263.
250. Ingelman-Sundberg, M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol. 2005, 207(2 Suppl), 52-56.
251. Xie, H.; Griskevicius, L.; Stahle, L.; Hassan, Z.; Yasar, U.; Rane, A.; Broberg, U.; Kimby, E.; Hassan, M. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur. J. Pharm. Sci. 2006, 27, 54-61.
252. Takada, K.; Arefayene, M.; Desta, Z.; Yarboro, C. H.; Boumpas, D. T.; Balow, J. E.; Flockhart, D. A.; Illei, G. G. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 2004, 50, 2202-2210.
253. Lindley, C.; Hamilton, G.; McCune, J. S.; Faucette, S.; Shord, S. S.; Hawke, R. L.; Wang, H.; Gilbert, D.; Jolley, S.; Yan, B.; LeCluyse, E. L. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab. Dispos. 2002, 30, 814-822.
254. Hustert, E.; Zibat, A.; Presecan-Siedel, E.; Eiselt, R.; Mueller, R.; Fuss, C.; Brehm, I.; Brinkmann, U.; Eichelbaum, M.; Wojnowski, L.; Burk, O. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 2001, 29, 1454-1459.
255. Lim, Y. P.; Liu, C. H.; Shyu, L. J.; Huang, J. D. Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet. Genomics 2005, 15, 337-341.
256. Dotzlaw, H.; Leygue, E.; Watson, P.; Murphy, L. C. The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin. Cancer Res. 1999, 5, 2103-2107.
257. Fukuen, S.; Fukuda, T.; Matsuda, H.; Sumida, A.; Yamamoto, I.; Inaba, T.; Azuma, J. Identification of the novel splicing variants for the hPXR in human livers. Biochem. Biophys. Res. Commun. 2002, 298, 433-438.
258. Hayes, J. D.; Flanagan, J. U.; Jowsey, I. R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 51-88.
259. Ye, Z.; Song, H. Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: A systematic review and meta-analysis. Eur. J. Cancer 2005, 41, 980-989.
260. Vester, U.; Kranz, B.; Zimmermann, S.; Buscher, R.; Hoyer, P. F. The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1. Pediatr. Nephrol. 2005, 20, 478-481.
261. Vasiliou, V.; Pappa, A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. Pharmacology 2000, 61, 192-198.
262. Crabb, D. W.; Matsumoto, M.; Chang, D.; You, M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc. Nutr. Soc. 2004, 63, 49-63.
263. Agarwal, D. P.; Goedde, H. W. Pharmacogenetics of alcohol metabolism and alcoholism. Pharmacogenetics 1992, 2, 48-62.
264. Rizzo, W. B.; Carney, G.; Lin, Z. The molecular basis of Sjogren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am. J. Hum. Genet. 1999, 65, 1547-1560.
265. Sillen, A.; Alderborn, A.; Pigg, M.; Jagell, S.; Wadelius, C. Detailed genetic and physical mapping in the Sjogren-Larsson syndrome gene region in 17p11.2. Hereditas 1998, 128, 245-250.
266. Andersson, B. S.; Murray, D. Model studies of cyclophosphamide resistance in human myeloid leukemia. Cancer Treat. Res. 2002, 112, 211-235.
267. Giorgianni, F.; Bridson, P. K.; Sorrentino, B. P.; Pohl, J.; Blakley, R. L. Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3. Biochem. Pharmacol. 2000, 60, 325-338.
268. Sladek, N. E.; Kollander, R.; Sreerama, L.; Kiang, D. T. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother. Pharmacol. 2002, 49, 309-321.
269. Wroczynski, P.; Laskowska, A.; Wierzchowski, J.; Szubert, A.; Polanski, J.; Slowiaczek, M. Aldehyde dehydrogenase isoenzymes in tumours - assay with possible prognostic value for oxazaphosphorine chemotherapy. Acta. Biochim. Pol. 1998, 45, 33-40.
270. Sachidanandam, R.; Weissman, D.; Schmidt, S. C.; Kakol, J. M.; Stein, L. D.; Marth, G.; Sherry, S.; Mullikin, J. C.; Mortimore, B. J.; Willey, D. L.; Hunt, S. E.; Cole, C. G.; Coggill, P. C.; Rice, C. M.; Ning, Z.; Rogers, J.; Bentley, D. R.; Kwok, P. Y.; Mardis, E. R.; Yeh, R. T.; Schultz, B.; Cook, L.; Davenport, R.; Dante, M.; Fulton, L.; Hillier, L.; Waterston, R. H.; McPherson, J. D.; Gilman, B.; Schaffner, S.; Van Etten, W. J.; Reich, D.; Higgins, J.; Daly, M. J.; Blumenstiel, B.; Baldwin, J.; Stange-Thomann, N.; Zody, M. C.; Linton, L.; Lander, E. S.; Altshuler, D. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409, 928-933.
271. Slattery, J. T.; Kalhorn, T. F.; McDonald, G. B.; Lambert, K.; Buckner, C. D.; Bensinger, W. I.; Anasetti, C.; Appelbaum, F. R. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J. Clin. Oncol. 1996, 14, 1484-1494.
272. Williams, M. L.; Wainer, I. W.; Embree, L.; Barnett, M.; Granvil, C. L.; Ducharme, M. P. Enantioselective induction of cyclophosphamide metabolism by phenytoin. Chirality 1999, 11, 569-574.
273. Ducharme, M. P.; Bernstein, M. L.; Granvil, C. P.; Gehrcke, B.; Wainer, I. W. Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers. Cancer Chemother. Pharmacol. 1997, 40, 531-533.
274. Yu, L. J.; Drewes, P.; Gustafsson, K.; Brain, E. G.; Hecht, J. E.; Waxman, D. J. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J. Pharmacol. Exp. Ther. 1999, 288, 928-937.
275. Yule, S. M.; Walker, D.; Cole, M.; McSorley, L.; Cholerton, S.; Daly, A. K.; Pearson, A. D.; Boddy, A. V. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab. Dispos. 1999, 27, 417-421.
276. Huitema, A. D.; Kerbusch, T.; Tibben, M. M.; Rodenhuis, S.; Beijnen, J. H. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother. Pharmacol. 2000, 46, 119-127.
277. Lokiec, F.; Santoni, J.; Weill, S.; Tubiana-Hulin, M. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. Anticancer Drugs 1996, 7, 893-896.
278. Brain, E. G.; Yu, L. J.; Gustafsson, K.; Drewes, P.; Waxman, D. J. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br. J. Cancer 1998, 77, 1768-1776.
279. Kerbusch, T.; Jansen, R. L.; Mathot, R. A.; Huitema, A. D.; Jansen, M.; van Rijswijk, R. E.; Beijnen, J. H. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin. Pharmacol. Ther. 2001, 70, 132-141.
280. Rekha, G. K.; Devaraj, V. R.; Sreerama, L.; Lee, M. J.; Nagasawa, H. T.; Sladek, N. E. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by chlorpropamide analogues. Biochem. Pharmacol. 1998, 55, 465-474.
281. Nakajima, T.; Takayama, T.; Miyanishi, K.; Nobuoka, A.; Hayashi, T.; Abe, T.; Kato, J.; Sakon, K.; Naniwa, Y.; Tanabe, H.; Niitsu, Y. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S- benzylcysteinyl-D-phenylglycine ethylester. J. Pharmacol. Exp. Ther. 2003, 306, 861-869.
282. Fahrig, R.; Heinrich, J. C.; Nickel, B.; Wilfert, F.; Leisser, C.; Krupitza, G.; Praha, C.; Sonntag, D.; Fiedler, B.; Scherthan, H.; Ernst, H. Inhibition of induced chemoresistance by cotreatment with (E)-5-(2-bromovinyl)- 2′-deoxyuridine (RP101). Cancer Res. 2003, 63, 5745-5753.
283. Yamauchi, T.; Keating, M. J.; Plunkett, W. UCN-01 (7- hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol. Cancer Ther. 2002, 1, 287-294.
284. Yamauchi, T.; Nowak, B. J.; Keating, M. J.; Plunkett, W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4- hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res. 2001, 7, 3580-3589.
285. Cai, Y.; Wu, M. H.; Xu-Welliver, M.; Pegg, A. E.; Ludeman, S. M.; Dolan, M. E. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res. 2000, 60, 5464-5469.
286. Muller, M. R.; Thomale, J.; Lensing, C.; Rajewsky, M. F.; Seeber, S. Chemosensitisation of alkylating agents by pentoxifylline, O6-benzylguanine and ethacrynic acid in haematological malignancies. Anticancer Res. 1993, 13, 2155-2159.
287. Gleave, M. E.; Monia, B. P. Antisense therapy for cancer. Nat. Rev. Cancer 2005, 5, 468-479.
288. Niitsu, Y.; Takahashi, Y.; Ban, N.; Takayama, T.; Saito, T.; Katahira, T.; Umetsu, Y.; Nakajima, T.; Ohi, M.; Kuga, T.; Sakamaki, S.; Matsunaga, T.; Hirayama, Y.; Kuroda, H.; Homma, H.; Kato, J.; Kogawa, K. A proof of glutathione S-transferase-pi-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell. Chem. Biol. Interact. 1998, 111-112, 325-332.
289. Moreb, J. S.; Maccow, C.; Schweder, M.; Hecomovich, J. Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J. Pharmacol. Exp. Ther. 2000, 293, 390-396.
290. Matsunaga, T.; Sakamaki, S.; Kuga, T.; Kuroda, H.; Kusakabe, T.; Akiyama, T.; Konuma, Y.; Hirayama, Y.; Kobune, M.; Kato, J.; Sasaki, K.; Kogawa, K.; Koyama, R.; Niitsu, Y. GST-pi gene-transduced hematopoietic progenitor cell transplantation overcomes the bone marrow toxicity of cyclophosphamide in mice. Hum. Gene Ther. 2000, 11, 1671-1681.
291. Muzio, G.; Trombetta, A.; Martinasso, G.; Canuto, R. A.; Maggiora, M. Antisense oligonucleotides against aldehyde dehydrogenase 3 inhibit hepatoma cell proliferation by affecting MAP kinases. Chem. Biol. Interact. 2003, 143-144, 37-43.
292. Tsui, P.; Rubenstein, M.; Guinan, P. Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model. Med. Oncol. 2004, 21, 339-348.
293. Thallinger, C.; Wolschek, M. F.; Maierhofer, H.; Skvara, H.; Pehamberger, H.; Monia, B. P.; Jansen, B.; Wacheck, V.; Selzer, E. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin. Cancer Res. 2004, 10, 4185-4191.
294. Simoes-Wust, A. P.; Schurpf, T.; Hall, J.; Stahel, R. A.; Zangemeister-Wittke, U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat. 2002, 76, 157-166.
295. Klasa, R. J. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Oncol. (Williston Park) 2004, 18, 25-31.
296. Koziner, B. Potential therapeutic applications of oblimersen in CLL. Oncol. (Williston Park) 2004, 18, 32-38.
297. Towatari, M.; Adachi, K.; Marunouchi, T.; Saito, H. Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line. Br. J. Haematol. 1998, 101, 548-551.
298. Arora, V. Antisense strategies for redirection of drug metabolism: using Paclitaxel as a model. Methods Mol. Med. 2004, 106, 273-292.
299. Yu, L. J.; Matias, J.; Scudiero, D. A.; Hite, K. M.; Monks, A.; Sausville, E. A.; Waxman, D. J. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos. 2001, 29, 304-312.
300. Chen, L.; Waxman, D. J. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des. 2002, 8, 1405-1416.
301. Jounaidi, Y.; Hecht, J. E.; Waxman, D. J. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 1998, 58, 4391-4401.
302. Chen, L.; Waxman, D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene
303. Patterson, L. H.; McKeown, S. R.; Robson, T.; Gallagher, R.; Raleigh, S. M.; Orr, S. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des. 1999, 14, 473-486.
304. Patterson, L. H.; Murray, G. I. Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 2002, 8, 1335-1347.
305. Chen, L.; Waxman, D. J.; Chen, D.; Kufe, D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 1996, 56, 1331-1340.
306. Jounaidi, Y.; Waxman, D. J. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res. 2004, 64, 292-303.
307. Braybrooke, J. P.; Slade, A.; Deplanque, G.; Harrop, R.; Madhusudan, S.; Forster, M. D.; Gibson, R.; Makris, A.; Talbot, D. C.; Steiner, J.; White, L.; Kan, O.; Naylor, S.; Carroll, M. W.; Kingsman, S. M.; Harris, A. L. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin. Cancer Res. 2005, 11, 1512-1520.
308. Scripture, C. D.; Sparreboom, A.; Figg, W. D. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005, 6, 780-789.
309. Chang, T. K.; Yu, L.; Maurel, P.; Waxman, D. J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997, 57, 1946-1954.
310. Yu, L.; Waxman, D. J. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N - dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab. Dispos. 1996, 24, 1254-1262.
311. de Jonge, M. E.; Huitema, A. D.; van Dam, S. M.; Beijnen, J. H.; Rodenhuis, S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother. Pharmacol. 2005, 55, 507-510.
312. Kohn, F. R.; Landkamer, G. J.; Sladek, N. E. Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557). Immunopharmacol. Immunotoxicol. 1987, 9, 163-176.
313. Weber, G. F.; Waxman, D. J. Denitrosation of the anti-cancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea catalyzed by microsomal glutathione S-transferase and cytochrome P450 monooxygenases. Arch. Biochem. Biophys. 1993, 307, 369-378.
314. Wilson, W. H.; Sorbara, L.; Figg, W. D.; Mont, E. K.; Sausville, E.; Warren, K. E.; Balis, F. M.; Bauer, K.; Raffeld, M.; Senderowicz, A. M.; Monks, A. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm. Clin. Cancer Res. 2000, 6, 415-421.
315. Heim, M. M.; Eberhardt, W.; Seeber, S.; Muller, M. R. Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines. J. Cancer Res. Clin. Oncol. 2000, 126, 198-204.
316. Smith, S. M.; Ludeman, S. M.; Wilson, L. R.; Springer, J. B.; Gandhi, M. C.; Dolan, M. E. Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells. Cancer Chemother. Pharmacol. 2003, 52, 291-302.
317. Klasa, R. J.; Bally, M. B.; Ng, R.; Goldie, J. H.; Gascoyne, R. D.; Wong, F. M. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res. 2000, 6, 2492-2500.
318. Koziner, B. Potential therapeutic applications of oblimersen in CLL. Oncol. (Huntingt) 2004, 18, 32-38.
319. Klasa, R. J. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Oncol. (Huntingt) 2004, 18, 25-31.
320. Muzio, G.; Canuto, R. A.; Trombetta, A.; Maggiora, M. Inhibition of cytosolic class 3 aldehyde dehydrogenase by antisense oligonucleotides in rat hepatoma cells. Chem. Biol. Interact. 2001, 130-132, 219-225.
321. Kan, O.; Griffiths, L.; Baban, D.; Iqball, S.; Uden, M.; Spearman, H.; Slingsby, J.; Price, T.; Esapa, M.; Kingsman, S.; Kingsman, A.; Slade, A.; Naylor, S. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther. 2001, 8, 473-482.